Back to Search Start Over

Two complement receptor one alleles have opposing associations with cerebral malaria and interact with α+thalassaemia

Two complement receptor one alleles have opposing associations with cerebral malaria and interact with α+thalassaemia

Authors :
D Herbert Opi
Olivia Swann
Alexander Macharia
Sophie Uyoga
Gavin Band
Carolyne M Ndila
Ewen M Harrison
Mahamadou A Thera
Abdoulaye K Kone
Dapa A Diallo
Ogobara K Doumbo
Kirsten E Lyke
Christopher V Plowe
Joann M Moulds
Mohammed Shebbe
Neema Mturi
Norbert Peshu
Kathryn Maitland
Ahmed Raza
Dominic P Kwiatkowski
Kirk A Rockett
Thomas N Williams
J Alexandra Rowe
Source :
eLife, Vol 7 (2018), Opi, D H, Swann, O, Macharia, A, Uyoga, S, Band, G, Ndila, C M, Harrison, E M, Thera, M A, Kone, A K, Diallo, D A, Doumbo, O K, Lyke, K E, Plowe, C V, Moulds, J M, Shebbe, M, Mturi, N, Peshu, N, Maitland, K, Raza, A, Kwiatkowski, D P, Rockett, K A, Williams, T & Rowe, A 2018, ' Two complement receptor one alleles have opposing associations with cerebral malaria and interact with α+thalassaemia ', eLIFE, vol. 7, e31579 . https://doi.org/10.7554/eLife.31579, eLife
Publication Year :
2018
Publisher :
eLife Sciences Publications Ltd, 2018.

Abstract

Malaria has been a major driving force in the evolution of the human genome. In sub-Saharan African populations, two neighbouring polymorphisms in the Complement Receptor One (CR1) gene, named Sl2 and McCb, occur at high frequencies, consistent with selection by malaria. Previous studies have been inconclusive. Using a large case-control study of severe malaria in Kenyan children and statistical models adjusted for confounders, we estimate the relationship between Sl2 and McCb and malaria phenotypes, and find they have opposing associations. The Sl2 polymorphism is associated with markedly reduced odds of cerebral malaria and death, while the McCb polymorphism is associated with increased odds of cerebral malaria. We also identify an apparent interaction between Sl2 and α+thalassaemia, with the protective association of Sl2 greatest in children with normal α-globin. The complex relationship between these three mutations may explain previous conflicting findings, highlighting the importance of considering genetic interactions in disease-association studies.<br />eLife digest Malaria kills more than half a million children in Africa every year. The disease is caused by the Plasmodium falciparum parasite, and mosquitos infected with the parasites spread them to humans when they bite. Once inside a human, the parasites infect the red blood cells. In severe cases, these red blood cells can stick to the walls of small blood vessels that supply the brain and so hinder the flow of oxygen, causing a coma. This is called cerebral malaria. Malaria can also result in the destruction of many oxygen-carrying red blood cells, which causes severe anemia. Both cerebral malaria and severe anemia can lead to death. Small changes (called mutations) in certain human genes can protect against malaria. Over time, mutations that protect people living in Africa from dying from malaria have been passed down through generations. A good example is the sickle cell mutation, which causes red blood cells to be of an unusual shape, but also affects the ability of malaria parasites to grow normally within red cells. Finding new mutations that protect against malaria may help scientists understand how severe malaria happens and eventually develop new drugs and vaccines against the disease. Some studies have found that mutations in a gene called complement receptor 1 (CR1) may be protective, although others have disagreed. Now, Opi, Swann et al. show that children with one of the CR1 mutations were one-third less likely to get cerebral malaria and half as likely to die as children without the mutation. In the study, genetic and health information on more than 5,500 children in Kenya were analyzed to see if the severity of malaria differed depending on whether they had a CR1 mutation. They also found that the CR1 mutation is only protective against severe malaria when the child does not have another malaria- protective mutation called α-thalassemia. In children with α-thalassemia, the CR1 mutation does not make a difference. The interaction between the CR1 mutation and α-thalassemia may explain why some studies did not show a benefit of CR1. If the researchers did not include α-thalassemia in their assessment, they could not have seen the whole picture. Future studies showing how the CR1 mutation protects against cerebral malaria could help identify new treatments that prevent severe disease or death. More study of interactions between genes that play a role in malaria may also be helpful.

Details

Language :
English
Volume :
7
Database :
OpenAIRE
Journal :
eLife
Accession number :
edsair.pmid.dedup....ec2668eb6b6cad7bb5ed1e01add0a19d
Full Text :
https://doi.org/10.7554/eLife.31579